- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03090178
Sleep & Quality of Life Evaluation of Patients With Atopic Dermatitis Based on E-diary on a Smartphone Application and Actigraphy (ACTISLEEP)
Sleep & Quality of Life Evaluation of Patients With Atopic Dermatitis Based on Real-world Data Collection With a Smartphone Application and a Validated Actigraphy Wristband
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
The main objective of the study is to demonstrate a medical hypothesis using a wristband actigraph: patients with moderate to severe atopic dermatitis have a poorer quality and quantity of sleep than healthy subject.
Secondary objetives are to assess the interest of a smartphone application in evaluating the quality of life of patients with moderate to severe atopic dermatitis in regard of those of healthy volunteers.
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
-
Paris, France
- Hôpital Saint-Louis
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
Patients :
- Subjects using a smartphone running Apple operating system (iOS 7 and above) or Android (version 2.2 and above)
- Subjects agreeing to wear the actigraphy wristband at night
- Subjects 18 years old or older
- Subjects affiliated to French Health Insurance
- Subjects treated for moderate to severe atopic dermatitis or atopic dermatitis exacerbation* *The stage of the atopic dermatitis will be assessed by using the Eczema Area and Severity Index (EASI), Body Surface Area (BSA) and Investigator Global Assessment (IGA). The EASI is an investigator-assessed instrument measuring the severity of clinical signs in atopic dermatitis. The EASI was identified as one of the best-validated outcome measures for atopic dermatitis.
A moderate to severe atopic dermatitis corresponds to:
- Eczema Area and Severity Index score ≥ 7.1
- Investigator Global Assessment ≥ 3
- Body Surface Area ≥ 10
Healthy volunters :
- Subjects using a smartphone running iOS (iOS 7 and above) or Android (version 2.2 and above)
- Subjects agreeing to wear the actigraphy wristband at night
- Subjects 18 years old or older
- Subjects affiliated to French Health Insurance
- Subjects without a dermatology disease
Non inclusion Criteria:
- -Illiterate subjects
- Subjects not proficient in French
Subject with a primary insomnia*
*Insomnia, sleep apnea and hypersomnia will be evaluated with respectively 3 tests:
- Insomnia Severity Index (ISI);
- Berlin Sleep Apnea Scale;
- Epworth Scale
- Subjects treated by hypnotic drugs
- Pregnant woman
- Subjects under guardianship
Exclusion criteria:
If a participant is taking hypnotic treatments during his study participation, he will be excluded from the clinical trial.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: OTHER
- Allocation: NON_RANDOMIZED
- Interventional Model: SEQUENTIAL
- Masking: NONE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
EXPERIMENTAL: Patients
Wear a wristband actigraph while sleeping and answer to quality of questionnaires on a smartphone application:
|
Measurement of sleep quality and quantity with wristband actigraph and evaluation of quality of life with electronic-Patient Report Outcome
|
ACTIVE_COMPARATOR: Healthy Volunteers
Wear of a wristband actigraph while sleeping and answer to quality of questionnaires on a smartphone application:
|
Measurement of sleep quality and quantity with wristband actigraph and evaluation of quality of life with electronic-Patient Report Outcome
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Sleep quality
Time Frame: 15 days
|
Measure of sleep quality
|
15 days
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Sleep quantity
Time Frame: 15 days
|
Measure of sleep quantity
|
15 days
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Quality of life
Time Frame: two times a day for 15 days
|
electronic patient report outcome on a secured mobile application
|
two times a day for 15 days
|
Collaborators and Investigators
Sponsor
Study record dates
Study Major Dates
Study Start (ACTUAL)
Primary Completion (ACTUAL)
Study Completion (ACTUAL)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (ACTUAL)
Study Record Updates
Last Update Posted (ACTUAL)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- P004
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Atopic Dermatitis Eczema
-
Jacob Pontoppidan ThyssenThe Novo Nordic FoundationRecruitingAtopic Dermatitis | Atopic Dermatitis Eczema | Atopic Dermatitis FlareDenmark
-
Kari NadeauKing's College London; National Institute of Allergy and Infectious Diseases... and other collaboratorsRecruitingEczema | Atopic Dermatitis | Atopic Dermatitis Eczema | Eczema, InfantileUnited States, United Kingdom
-
University of California, DavisCompletedAtopic Dermatitis | Hand Eczema | Atopic Eczema | Infantile EczemaUnited States
-
Catalysis SLCompletedAtopic Dermatitis | Atopic Dermatitis Eczema | Atopic Dermatitis and Related Conditions | Atopic Dermatitis \(AD\)Serbia
-
Petra LarmoCliniscan LtdTerminated
-
Groningen Research Institute for Asthma and COPDNumico Research Wageningen, the NetherlandsCompletedAtopic Dermatitis | Atopic Eczema | Infantile EczemaNetherlands
-
ShaperonRecruitingAtopic Dermatitis | Atopic Dermatitis Eczema | Atopic Dermatitis of ScalpUnited States
-
University of California, San FranciscoSanofi; Regeneron PharmaceuticalsRecruitingEczema | Atopic Dermatitis | Atopic Dermatitis Eczema | Atopic Dermatitis and Related ConditionsUnited States
-
PfizerActive, not recruitingEczema | Atopic Dermatitis | Eczema, Atopic | Atopic Dermatitis, UnspecifiedUnited States, Canada, Czechia, Poland
-
Academisch Medisch Centrum - Universiteit van Amsterdam...ZonMw: The Netherlands Organisation for Health Research and DevelopmentRecruitingAtopic Dermatitis | Atopic Dermatitis EczemaNetherlands
Clinical Trials on electronic-Patient Report Outcome and wear of a wristband actigraph
-
Harbin Medical UniversityRecruitingCancer | Colorectal Cancer MetastaticChina
-
Royal Marsden NHS Foundation TrustUnknownBreast CancerUnited Kingdom
-
Memorial Sloan Kettering Cancer CenterNational Institutes of Health (NIH)CompletedOvarian Cancer | Fallopian Tube Cancer | Vulvar Cancer | Vaginal Cancer | Peritoneal Cancer | Uterine CancerUnited States